Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
Neurology
Journal
Overview
Identity
Overview
Publication Venue For
Prediction of Naming Outcome With FMRI Language Lateralization in Left Temporal Epilepsy Surgery
. 98:E2337-E2346.
2022
Prognosis After Stroke: Do We Have What We Need to Talk With Patients and Their Families?
2022
Nucleosides Associated With Incident Ischemic Stroke in the REGARDS and JHS Cohorts
. 98:E2097-E2107.
2022
Impact of Telestroke Implementation on Emergency Department Transfer Rate
. 98:E1617-E1625.
2022
Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study
. 98:E376-E389.
2022
Disparities of Care in Post-Concussive Pediatric Patients
. 98:S13.
2022
Efficacy of Outpatient Infusion Therapy in Pediatric Patients With Post-Concussive Headaches
. 98:S14-S15.
2022
Evaluation of Sports-Related Concussion in Children (5-12) and Adolescents (13-18)
. 98:S12-S13.
2022
Multiple Sclerosis Diagnostic Criteria: Moving Ahead or Walking in Place?
. 98:12-13.
2022
Representation of Women in Stroke Clinical Trials: A Review of 281 Trials Involving More Than 500,000 Participants
. 97:e1768-e1774.
2021
Safety and Efficacy of Natalizumab as Adjunctive Therapy for People With Drug-Resistant Epilepsy: A Phase 2 Study
. 97:e1757-e1767.
2021
Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis
. 97:E1560-E1570.
2021
Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum
. 97:e1334-e1342.
2021
Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas: Implications for Clinical Trials
. 97:S15-S24.
2021
Sex and Race Differences in the Risk of Ischemic Stroke Associated With Fasting Blood Glucose in REGARDS
. 97:e684-e694.
2021
Status and Recommendations for Incorporating Biomarkers for Cutaneous Neurofibromas Into Clinical Research
. 97:S42-S49.
2021
Silent Myocardial Infarction and Subsequent Ischemic Stroke in the Cardiovascular Health Study
. 97:e436-e443.
2021
Neighborhood Socioeconomic Status and Stroke Incidence: A Systematic Review
. 96:897-907.
2021
Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration
. 96:e2296-e2312.
2021
Repurposing Domperidone in Secondary Progressive Multiple Sclerosis: A Simon 2-Stage Phase 2 Futility Trial
. 96:e2313-e2322.
2021
Expanding the Spectrum of Chronic Immune Sensory Polyradiculopathy: CISP-Plus
. 96:e2078-e2089.
2021
Association of De Novo RNF213 Variants With Childhood Onset Moyamoya Disease and Diffuse Occlusive Vasculopathy
. 96:e1783-e1791.
2021
Prospective Analysis of Leisure-Time Physical Activity in Midlife and Beyond and Brain Damage on MRI in Older Adults
. 96:e964-e974.
2021
Dystonia and Tremor: A Cross-Sectional Study of the Dystonia Coalition Cohort
. 96:e563-e574.
2021
Paraneoplastic Myeloneuropathies: Clinical, Oncologic, and Serologic Accompaniments
. 96:e632-e639.
2021
Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a
. 96:e214-e227.
2021
Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis
. 96:e111-e120.
2021
Racial Differences in Atrial Cardiopathy Phenotypes in Ischemic Stroke Patients.
2020
Bing-Neel syndrome mimicking a meningioma
. 95:838-839.
2020
Pediatric Multiple Sclerosis Severity Score in a large US cohort
. 95:e1844-e1853.
2020
Cardiovascular risk factors and accelerated cognitive decline in midlife: The CARDIA Study
. 95:e839-e846.
2020
Minimal manifestation status and prednisone withdrawal in the MGTX trial
. 95:e755-e766.
2020
Comorbidity is associated with disease activity in MS: Findings from the CombiRx trial
. 95:e446-e456.
2020
The CREST-2 experience with the evolving challenges of COVID-19: A clinical trial in a pandemic
. 95:29-36.
2020
Revised Self-Monitoring Scale: A potential endpoint for frontotemporal dementia clinical trials
. 94:e2384-e2395.
2020
Author response: Dietary patterns during adulthood and cognitive performance in midlife: The CARDIA study
. 94:636.
2020
Defining research priorities in dystonia
. 94:526-537.
2020
Phrenic neuropathy water immersion dyspnea: Clinical findings and need for patient counseling
. 94:e1314-e1319.
2020
Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?
. 94:481-494.
2020
Education Research: Multiple sclerosis and neuroimmunology fellowship training status in the United States
. 94:495-500.
2020
Child Neurology: Arterial ischemic stroke in a 12-year-old patient with cardiac myxomas
. 94:e1103-e1106.
2020
Unraveling the risk factors for spontaneous intracerebral hemorrhage among West Africans
. 94:e998-e1012.
2020
Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing
. 93:e1452-e1462.
2019
Child Neurology: Spastic paraparesis and dystonia with a novel ADCY5 mutation
. 93:510-514.
2019
Hand stereotypies: Lessons from the Rett Syndrome Natural History Study
. 92:E2594-E2603.
2019
Reader response: Alien hand syndrome
. 92:1070.
2019
Inflammatory cytokines and ischemic stroke risk: The REGARDS cohort
. 92:E2375-E2384.
2019
How should we normalize regional volume abnormalities in childhood neurodegenerative disorders?
. 92:779-780.
2019
Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome
. 92:E1912-E1925.
2019
A survey of risk tolerance to multiple sclerosis therapies
. 92:E1634-E1642.
2019
Dietary patterns during adulthood and cognitive performance in midlife: The CARDIA study
. 92:E1589-E1599.
2019
A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS
. 92:469-480.
2019
The prevalence of MS in the United States: A population-based estimate using health claims data
. 92:E1029-E1040.
2019
Serum magnesium and calcium levels in relation to ischemic stroke: Mendelian randomization study
. 92:E944-E950.
2019
Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases
. 92:329-337.
2019
Reducing neurodisparity: Recommendations of the 2017 AAN Diversity Leadership Program
. 92:e274-e280.
2019
Teaching neuroimages: Facial swelling and intracerebral hemorrhage from venous hypertension in a dialysis patient
. 92:E521-E522.
2019
Word comprehension in temporal cortex and Wernicke area: A PPA perspective
. 92:E224-E233.
2019
Clinical and neural responses to cognitive behavioral therapy for functional tremor
. 93:1-12.
2019
PCNT point mutations and familial intracranial Aneurysms
. 91:E2170-E2181.
2018
Racial differences in recurrent ischemic stroke risk and recurrent stroke case fatality
. 91:E1741-E1750.
2018
Sleep duration and risk of incident stroke by age, sex, and race the REGARDS study
. 91:E1702-E1709.
2018
Outcomes after carotid endarterectomy among elderly dual Medicare-Medicaid-eligible patients
. 91:E1553-E1558.
2018
Clinical trial design for cutaneous neurofibromas
. 91:S31-S37.
2018
Cutaneous neurofibromas: Current clinical and pathologic issues
. 91:S5-S13.
2018
New diagnosis of cancer and the risk of subsequent cerebrovascular events
. 90:E2025-E2033.
2018
Cerebellar volume as an imaging marker of development in infants with tuberous sclerosis complex.
. 90:e1493-e1500.
2018
Diet quality is associated with disability and symptom severity in multiple sclerosis
. 90:E1-E11.
2018
MicroRNAs in CSF as prodromal biomarkers for Huntington disease in the PREDICT-HD study
. 90:E264-E272.
2018
Cognitive trajectories over 4 years among HIV-infected women with optimal viral suppression
. 89:1594-1603.
2017
Cognitive trajectories over 4 years among HIV-infected women with optimal viral suppression
. 89:1594-1603.
2017
Author response: High hypothetical interest in physician-assisted death in multiple sclerosis
. 89:1429-1430.
2017
Child Neurology: Childhood basilar artery occlusion and stroke
. 89:e68-e70.
2017
Author response: Practice guideline summary: Use of fMRI in the presurgical evaluation of patients with epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology
. 89:640-641.
2017
Permanent CSF shunting after intraventricular hemorrhage in the CLEAR III trial
. 89:355-362.
2017
Body mass index and outcome after revascularization for symptomatic carotid artery stenosis
. 88:2052-2060.
2017
Child Neurology: LAMA2 muscular dystrophy without contractures
. 88:e199-e203.
2017
Effect of a long-term intensive lifestyle intervention on prevalence of cognitive impairment
. 88:2026-2035.
2017
Clinical Reasoning: A 45-year-old man with weakness and myalgia after orthopedic surgery
. 88:e185-e189.
2017
Racial differences in statin adherence following hospital discharge for ischemic stroke
. 88:1839-1848.
2017
Evidence for a causal relationship between low Vitamin D, high BMI, and pediatric-onset MS
. 88:1623-1629.
2017
High hypothetical interest in physician-assisted death in multiple sclerosis
. 88:1528-1534.
2017
Natalizumab-associated PML: Challenges with incidence, resulting risk, and risk stratification
. 88:1197-1205.
2017
Child Neurology: Rocky Mountain spotted fever encephalitis
. 88:e92-e95.
2017
Long-term functional outcome in patients with acquired infections after acute spinal cord injury
. 88:892-900.
2017
Practice guideline summary: Use of fMRI in the presurgical evaluation of patients with epilepsy
. 88:395-402.
2017
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease
. 88:152-159.
2017
Neonatal seizures in premature infants with IVH: are myoclonic jerks seizures?
. 88:92-95.
2017
Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1
. 87:2575-2584.
2016
Effect of aphasia on acute stroke outcomes
. 87:2348-2354.
2016
Neighborhood socioeconomic index and stroke incidence in a national cohort of blacks and whites
. 87:2340-2347.
2016
Twelve-month recovery of medical decision-making capacity following traumatic brain injury
. 87:1052-1059.
2016
Pediatric multiple sclerosis Clinical features and outcome
. 87:S74-S81.
2016
Symptom profiles of autism spectrum disorder in tuberous sclerosis complex
. 87:766-772.
2016
Current status and recommendations for biomarkers and biobanking in neurofibromatosis
. 87:S40-S48.
2016
Type 2 diabetes mellitus is associated with brain atrophy and hypometabolism in the ADNI cohort
. 87:595-600.
2016
Health insurance affects the use of disease-modifying therapy in multiple sclerosis
. 87:365-374.
2016
Recommendations for observational studies of comorbidity in multiple sclerosis.
. 86:1446-1453.
2016
The challenge of comorbidity in clinical trials for multiple sclerosis.
. 86:1437-1445.
2016
Hostile attitudes and effortful coping in young adulthood predict cognition 25 years later
. 86:1227-1234.
2016
Differences in the role of black race and stroke risk factors for first vs recurrent stroke
. 86:637-642.
2016
Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report
. 86:245-252.
2016
New-onset refractory status epilepticus
. 85:1604-1613.
2015
Author response
. 85:742-743.
2015
Emerging Subspecialties in Neurology: Neurorehabilitation
. 85:e50-e52.
2015
DNA methylation slows effects of C9orf72 mutations
. 84:1616-1617.
2015
Ictal adipokines are associated with pain severity and treatment response in episodic migraine
. 84:1409-1418.
2015
Marijuana Usage and Disability in MS in the NARCOMS Registry
. April 06, 2015; 84 (14 Supplement):P1.140-P1.140.
2015
Long-term impact of stroke on family caregiver well-being: A population-based case-control study
. 84:1323-1329.
2015
Differences in Alzheimer disease clinical trial outcomes based on age of the participants
. 84:1121-1127.
2015
Placebo effect of medication cost in Parkinson disease: A randomized double-blind study
. 84:794-802.
2015
Quality improvement in neurology: primary headache quality measures.
. 84:200-203.
2015
Global investigation and meta-analysis of the C9orf72 (G4C2)n repeat in Parkinson disease.
. 83:1906-1913.
2014
Clinical response to Bevacizumab in schwannomatosis
. 83:1986-1987.
2014
Protective environmental factors for neuromyelitis optica
. 83:1923-1929.
2014
ABO blood type, factor VIII, and incident cognitive impairment in the REGARDS cohort
. 83:1271-1276.
2014
JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene.
. 83:727-732.
2014
Defining the clinical course of multiple sclerosis: The 2013 revisions
. 83:278-286.
2014
Spectrogram screening of adult EEGs is sensitive and efficient
. 83:56-64.
2014
Paroxysmal hypnogenic dyskinesia
. 82:1935.
2014
Feasibility of Huntington disease trials in the disease prodrome
. 82:824-825.
2014
Randomized Evaluation of Carotid Occlusion and Neurocognition (RECON) trial
. 82:744-751.
2014
Mortality in patients with multiple sclerosis
. 81:184-192.
2013
Report of stroke-like symptoms predicts incident cognitive impairment in a stroke-free cohort
. 81:113-118.
2013
Management of carotid stenosis in women consensus document
. 80:2258-2268.
2013
Cerebral hemodynamics and cognitive decline: Swimming against the current
. 80:2086-2087.
2013
Pearls and Oy-sters: Acute ischemic stroke caused by atypical thrombotic thrombocytopenic purpura
. 80.
2013
Clinicopathologic variability of the GRN A9D mutation, including amyotrophic lateral sclerosis
. 80:1771-1777.
2013
Adherence to a Mediterranean diet and risk of incident cognitive impairment
. 80:1684-1692.
2013
Effect of duration and age at exposure to the Stroke Belt on incident stroke in adulthood
. 80:1655-1661.
2013
Disability in multiple sclerosis: A reference for patients and clinicians
. 80:1018-1024.
2013
Functional impairment in progressive supranuclear palsy
. 80:380-384.
2013
Recommendations for imaging tumor response in neurofibromatosis clinical trials.
. 81.
2013
Assessment of cortical and striatal involvement in 523 Huntington disease brains
. 79:1708-1715.
2012
Growth failure and outcome in Rett syndrome: Specific growth references
. 79:1653-1661.
2012
Racial differences in albuminuria, kidney function, and risk of stroke
. 79:1686-1692.
2012
What is it about neighborhood characteristics that influence survival after a stroke or TIA?
. 79:1190-1191.
2012
Prevalence and significance of stroke symptoms among patients receiving maintenance dialysis
. 79:981-987.
2012
Novel late-onset Alzheimer disease loci variants associate with brain gene expression.
. 79:221-228.
2012
Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)
. 79:163-169.
2012
Treatment consent capacity in patients with traumatic brain injury across a range of injury severity
. 78:1472-1478.
2012
Cognitive performance of GBA mutation carriers with early-onset PD The CORE-PD study
. 78:1434-1440.
2012
Survival in MS A randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial
. 78:1315-1322.
2012
CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion
. 78:690-695.
2012
Incidence and prevalence of epilepsy among older US Medicare beneficiaries
. 78:448-453.
2012
Carotid stenosis: To revascularize, or not to revascularize: That is the question
. 78:294.
2012
Carotid stenosis: to revascularize, or not to revascularize: that is the question.
. 78:294.
2012
Cerebral hemodynamics and cognitive impairment: Baseline data from the RECON trial
. 78:250-255.
2012
Evaluation of safety monitoring guidelines based on MRI lesion activity in multiple sclerosis
. 77:2089-2096.
2011
Reply from the authors
. 77.
2011
Clinical severity and quality of life in children and adolescents with Rett syndrome
. 77:1812-1818.
2011
Quantifying physical decline in juvenile neuronal ceroid lipofuscinosis (Batten disease)
. 77:1801-1807.
2011
Vascular risk factors and cognitive impairment in a stroke-free cohort
. 77:1729-1736.
2011
To the editor
. 77.
2011
A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS.
. 77:1551-1560.
2011
GFAP mutations, age at onset, and clinical subtypes in Alexander disease
. 77:1287-1294.
2011
Prevalence, sensitivity, and specificity of chronic cerebrospinal venous insufficiency in MS
. 77:138-144.
2011
Common viruses associated with lower pediatric multiple sclerosis risk
. 76:1989-1995.
2011
Behavioral therapy to treat urinary incontinence in Parkinson disease
. 76:1631-1634.
2011
Interferon β-1b and glatiramer acetate effects on permanent black hole evolution
. 76:1222-1228.
2011
NMO Spectrum Disorder in Children and Adolescents
. 76:A395-A396.
2011
Pituitary Adenoma Complicated By Multifocal Fibrosclerosis Involving Sella and Retroperitoneum
. 76:A250-A251.
2011
Recurrent Demyelinating Events Following Pediatric Optic Neuritis (pON)
. 76:A394-A394.
2011
Racial and geographic differences in fish consumption: The regards study
. 76:154-158.
2011
Neurocognitive sequelae in African American and Caucasian children with multiple sclerosis
. 75:2097-2102.
2010
Association of reversed Robin Hood syndrome with risk of stroke recurrence
. 75:2003-2008.
2010
A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2
. 75:1189-1194.
2010
A case of neurosarcoidosis successfully treated with rituximab
. 75:568-570.
2010
Reply from the authors
. 74:1554-1555.
2010
Epilepsy and the natural history of Rett syndrome
. 74:909-912.
2010
25-Hydroxyvitamin D levels and cognitive performance and decline in elderly men
. 74:33-41.
2010
Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis
. 74:1041-1047.
2010
Younger children with MS have a distinct CSF inflammatory profile at disease onset
. 74:399-405.
2010
Association of higher diastolic blood pressure levels with cognitive impairment
. 73:589-595.
2009
Reply from the authors
. 73:571.
2009
Dietary intake in adults at risk for Huntington disease: Analysis of PHAROS Research Participants
. 73:385-392.
2009
Subthalamic nucleus and its connections: Anatomic substrate for the network effects of deep brain stimulation
. 72:1110.
2009
Depression in Pediatric MS Patients Correlates with Increased Disease Severity and Selective Neuropsychological Deficits
. 72:A371-A372.
2009
Hepatitis vaccines and pediatric multiple sclerosis: Does timing or type matter?
. 72:870-871.
2009
Personality and lifestyle in relation to dementia incidence
. 72:253-259.
2009
Comorbidity delays diagnosis and increases disability at diagnosis in MS
. 72:117-124.
2009
A cross-sectional study of bone health in multiple sclerosis
. 73:1394-1398.
2009
Declining financial capacity in mild cognitive impairment: A 1-year longitudinal study
. 73:928-934.
2009
Declining financial capacity in patients with MCI: A one-year longitudinal study
. 73:928-934.
2009
Editorial: Relapses in multiple sclerosis: Important or not?
. 73:1612-1613.
2009
Medical decision-making capacity in patients with malignant glioma
. 73:2086-2092.
2009
Optic neuropathy in patients with glioblastoma receiving bevacizumab
. 73:1924-1926.
2009
Invited Article: The US health care system: Part 1: Our current system
. 71:1907-1913.
2008
Invited article: The US health care system: Part 2: Proposals for improvement and comparison to other systems
. 71:1914-1920.
2008
Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis: Reply
. 71:1747-1748.
2008
A novel PRNP-P105S mutation associated with atypical prion disease and a rare PrPSc conformation
. 71:1431-1438.
2008
CNS aquaporin-4 autoimmunity in children
. 71:93-100.
2008
Haplotypes and gene expression implicate the MAPT region for Parkinson disease: The GenePD Study
. 71:28-34.
2008
Ethics of placebo-controlled clinical trials in multiple sclerosis: A reassessment
. 70:1134-1140.
2008
Investigating genotype-phenotype relationships in Rett syndrome using an international data set
. 70:868-875.
2008
Responsiveness and predictive values in PPMS: An uncertain message
. 70:1061-1062.
2008
Specific mutations in Methyl-CpG-Binding Protein 2 confer different severity in Rett syndrome
. 70:1313-1321.
2008
Study of a Swiss dopa-responsive dystonia family with a deletion in GCH1: Redefining DYT14 as DYT5
. 70:1377-1383.
2008
Erratum: Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease (Neurology (2007) 68, (272-276))
. 69:617.
2007
Rasmussen syndrome and CNS granulomatous disease with NOD2/CARD15 mutations
. 69:640-643.
2007
Higher IgG index found in African Americans versus Caucasians with multiple sclerosis
. 69:68-72.
2007
MR tractography depicting damage to the arcuate fasciculus in a patient with conduction aphasia [6]
. 69:321.
2007
Disparities in the management of multiple sclerosis-related bladder symptoms
. 68:1971-1978.
2007
Migraine and retinal microvascular abnormalities: The Atherosclerosis Risk in Communities Study
. 68:1694-1700.
2007
Predictors of diagnosis in Huntington disease
. 68:1710-1717.
2007
Nothing out of sequence? Think deletion!
. 68:975-976.
2007
Reply from the authors [8]
. 68:965.
2007
NF1 plexiform neurofibroma growth rate by volumetric MRI: Relationship to age and body weight
. 68:643-647.
2007
A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease
. 68:20-28.
2007
Acute disseminated encephalomyelitis
. 68.
2007
Clinical features of children and adolescents with multiple sclerosis
. 68.
2007
Hippocampal 1H-MRSI correlates with severity of depression symptoms in temporal lobe epilepsy
. 68:364-368.
2007
MRI features of pediatric multiple sclerosis
. 68.
2007
Optical coherence tomography and disease subtype in multiple sclerosis
. 69:2085-2092.
2007
Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease
. 68:272-276.
2007
Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease (Neurolgy (2007) 68, (272-276))
. 69:2187.
2007
Relation of vision to global and regional brain MRI in multiple sclerosis
. 69:2128-2135.
2007
Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis
. 69:1603-1609.
2007
Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age: The GenePD study
. 67:2206-2210.
2006
Improving caregiver well-being delays nursing home placement of patients with Alzheimer disease
. 67:1592-1599.
2006
The Motor Activity Log-28: Assessing daily use of the hemiparetic arm after stroke
. 67:1189-1194.
2006
Early progressive encephalopathy in boys and MECP2 mutations
. 67:164-166.
2006
Quality improvement in acute stroke: The New York State Stroke Center Designation Project
. 67:88-93.
2006
Elevated troponin levels are associated with higher mortality following intracerebral hemorrhage
. 66:1330-1334.
2006
Does multiple sclerosis-associated disability differ between races?
. 66:1235-1240.
2006
Futility studies: Spending a little to save a lot
. 66:626-627.
2006
Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis [3]
. 66:954.
2006
A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease
. 66:664-671.
2006
Elevated CSF free kappa light chains correlate with disability prognosis in multiple sclerosis
. 67:1288-1290.
2006
Perception of motor strength and stimulus magnitude are correlated in stroke patients
. 66:1444-1446.
2006
BDNF genetic variants are associated with onset age of familial Parkinson disease: GenePD Study
. 65:1823-1825.
2005
Occupation and parkinsonism in three movement disorders clinics
. 65:1430-1435.
2005
Changes in the ascertainment of multiple sclerosis
. 65:1066-1070.
2005
MRI as a marker for disease heterogeneity in multiple sclerosis
. 65:1071-1076.
2005
Frontotemporal dementia progresses to death faster than Alzheimer disease
. 65:719-725.
2005
Does gender parity exist in Fabry disease?
. 65:508-509.
2005
Blood harmane concentrations and dietary protein consumption in essential tremor
. 65:391-396.
2005
Efficacy of rapid IV administration of valproic acid for status epilepticus [3] (multiple letters)
. 65:500-501.
2005
Medical decision-making in neurodegenerative disease: Mild AD and PD with cognitive impairment
. 65:483-485.
2005
A clinical rating scale for Batten disease: Reliable and relevant for clinical trials
. 65:275-279.
2005
Spinal fluid 5-methyltetrahydrofolate levels are normal in Rett syndrome
. 64:2151-2152.
2005
Headache, cerebrovascular symptoms, and stroke: The atherosclerosis risk in communities study
. 64:1573-1577.
2005
Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis
. 64:992-995.
2005
Unilateral cerebral peduncular atrophy progresses for decades after stroke
. 64:A110-A110.
2005
Efficacy of rapid IV administration of valproic acid for status epilepticus
. 64:353-355.
2005
Training, competency, and credentialing standards for diagnostic cervicocerebral angiography, carotid stenting, and cerebrovascular intervention: a joint statement from the American Academy of Neurology, the American Association of Neurological Surgeons, the American Society of Interventional and Therapeutic Neuroradiology, the American Society of Neuroradiology, the Congress of Neurological Surgeons, the AANS/CNS Cerebrovascular Section, and the Society of Interventional Radiology.
. 64:190-198.
2005
Training, competency, and credentialing standards for diagnostic cervicocerebral angiograpny, carotid stenting, and cerebrovascular intervention: A Joint Statement from the American Academy of Neurology, the American Association of Neurological Surgeons, the American Society of Interventional and Therapeutic Neuroradiology, and the Society of Interventional Radiology
. 64:190-198.
2005
Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders
. 65:1941-1949.
2005
Intracranial arterial dolichoectasia is associated with enlarged descending thoracic aorta [1] (multiple letters)
. 65:1681-1682.
2005
Multifocal motor sensory demyelinating neuropathy: Inflammatory demyelinating polyradiculoneuropathy
. 65:1639-1642.
2005
Pacemaker-induced tachycardia caused by inappropriate response to parkinsonian tremor
. 65:1676-1677.
2005
Migraine and other headaches: Associations with Rose angina and coronary heart disease
. 63:2233-2239.
2004
Cortical reorganization in malformations of cortical development: A magnetoencephalographic study
. 63:1818-1824.
2004
The evolving role of monoamine oxidase inhibitors in the treatment of Parkinson's disease
. 63.
2004
Sensitivity of 14-3-3 protein test varies in subtypes of sporadic Creutzfeldt-Jakob disease
. 63:436-442.
2004
Disorganized search on cancellation is not a consequence of neglect
. 63:78-84.
2004
Eclampsia, hippocampal sclerosis, and temporal lobe epilepsy: Accident or association?
. 62:1352-1356.
2004
Ophthalmologic features of Parkinson's disease
. 62:177-180.
2004
Frequency of epilepsy in patients with psychogenic seizures monitored by video-EEG
. 61:1791-1792.
2003
A haplotype at the PARK3 locus influences onset age for Parkinson's disease: The GenePD study
. 61:1557-1561.
2003
Adenosine A2A receptor modulation of motor systems for symptomatic therapy in Parkinson's disease.
. 61:S30-S31.
2003
Effect of relapses on development of residual deficit in multiple sclerosis
. 61:1528-1532.
2003
II: A
2A
receptor modulation for symptomatic therapy in Parkinson's disease: Adenosine A
2A
receptor modulation of motor systems in PD
. 61.
2003
Subacute inflammatory demyelinating polyneuropathy
. 61:1507-1512.
2003
Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite
. 61:1367-1373.
2003
Teddy bears: An observational finding in patients with non-epileptic events
. 61:714-715.
2003
A randomized controlled study of the acute and chronic effects of cooling therapy for MS.
. 60:1955-1960.
2003
Neurotoxicity following addition of intravenous valproate to lamotrigine therapy
. 60:1991-1992.
2003
A note of caution on correlation between sibling pairs [6] (multiple letters)
. 60:1561.
2003
Genetic polymorphisms of the N-acetyltransferase genes and risk of Parkinson's disease
. 60:1189-1191.
2003
Predictors of nursing home placement in Huntington disease
. 60:998-1001.
2003
Tic reduction with pergolide in a randomized controlled trial in children
. 60:606-611.
2003
Tic reduction in Tourette Syndrome: improvement with pergolide in a randomized controlled trial in children
. 60:606-611.
2003
Eight-year follow-up study of brain atrophy in patients with MS
. 59:1412-1420.
2002
Weight loss in early stage of Huntington's disease
. 59:1325-1330.
2002
Benefit of interferon β-1a on MSFC progression in secondary progressive MS
. 59:679-687.
2002
Clinical and genetic heterogeneity in benign hereditary chorea
. 59:579-584.
2002
Dopamine transmission in DYT1 dystonia: A biochemical and autoradiographical study
. 59:445-448.
2002
Language lateralization in left-handed and ambidextrous people: fMRI data
. 59:238-244.
2002
Molecular findings in symptomatic and pre-symptomatic Alexander disease patients
. 58:1494-1500.
2002
Plexiform neurofibromas in NF1: Toward biologic-based therapy
. 58:1461-1470.
2002
Porphyria presenting with bilateral radial motor neuropathy: Evidence of a novel gene mutation
. 58:1118-1121.
2002
HLA-A2 homozygosity but not heterozygosity is associated with Alzheimer disease
. 58:973-975.
2002
Depression associated with Parkinson's disease: Clinical features and treatment
. 58.
2002
Treatment of ADHD in children with tics: A randomized controlled trial
. 58:527-536.
2002
Insomnia associated with thalamic involvement in E200K Creutzfeldt-Jakob disease
. 58:362-367.
2002
Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults
. 58:368-372.
2002
Epidemiologic study of 203 sibling pairs with Parkinson's disease: The GenePD study
. 58:79-84.
2002
Genome-wide scan for Parkinson's disease: The GenePD study
. 57:1124-1126.
2001
Bilateral hippocampal atrophy: Consequences to verbal memory following temporal lobectomy
. 57:597-604.
2001
Chromosome 22q and the mind-brain interface: Bedside to bench to bedside
. 57:377-378.
2001
Large-fiber neuropathy in distal sensory neuropathy with normal routine nerve conduction
. 56:1570-1572.
2001
Parkinson's disease, CYP2D6 polymorphism, and age
. 56:1363-1370.
2001
Use of the multiple sclerosis functional composite to predict disability in relapsing MS
. 56:1324-1330.
2001
Left vagus nerve stimulation suppresses experimentally induced pain [3] (multiple letters)
. 56:985-986.
2001
Chronic thalamic stimulation for treatment of dystonic paroxysmal nonkinesigenic dyskinesia
. 56:268-270.
2001
Postictal stability of proton magnetic resonance spectroscopy imaging (
1
H-MRSI) ratios in temporal lobe epilepsy
. 56:251-253.
2001
Cardiovascular risk factors and cognitive decline in middle-aged adults
. 56:42-48.
2001
Competency to consent to medical treatment in cognitively impaired patients with Parkinson's disease
. 56:17-24.
2001
Sensory Guillain-Barré syndrome
. 56:82-86.
2001
An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment guidelines
. 56.
2001
Four-year incidence of psychogenic nonepileptic seizures in adults in Hamilton County, OH
. 55:1561-1563.
2000
Pelizaeus-Merzbacher disease: Splice sites are nice sites for disease expression
. 55:1072-1073.
2000
The experience of Wernicke's aphasia
. 55:1222-1224.
2000
Low mini-mental status predicts mortality in asymptomatic carotid arterial stenosis
. 55:30-34.
2000
Low mini-mental status predicts mortality in asymptomatic carotid arterial stenosis. Asymptomatic Carotid Atherosclerosis Study investigators.
. 55:30-34.
2000
Visual attention impairments in Alzheimer's disease
. 54:1954-1959.
2000
Pure topographic disorientation: A distinctive syndrome with varied localization
. 54:1864-1866.
2000
Enlarged parietal foramina: Association with cerebral venous and cortical anomalies
. 54:1175-1178.
2000
Intrarater and interrater reliability of the MS functional composite outcome measure
. 54:802-806.
2000
A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome
. 54:603-607.
2000
Arm levitation in progressive supranuclear palsy.
. 54:774.
2000
Rate of functional decline in Huntington's disease
. 54:452-458.
2000
Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults [2] (multiple letters)
. 54:270-272.
2000
Pure topographic disorientation: A distinctive syndrome with varied localization
. 54:575-578.
2000
Cognitive correlates of
1
H MRSI-detected hippocampal abnormalities in temporal lobe epilepsy
. 53:2052-2058.
1999
Error behaviors associated with loss of competency in Alzheimer's disease
. 53:1983-1992.
1999
Visual dysfunction in patients receiving vigabatrin: Clinical and electrophysiologic findings
. 53:2082-2087.
1999
Eliminating institutional child abuse: A road too well traveled
. 53:1617-1621.
1999
Juvenile Parkinson's disease with REM sleep behavior disorder, sleepiness, and daytime REM onset
. 53:1868-1870.
1999
Neurologic complications of pediatric lung transplantation
. 53:1542-1549.
1999
Subjective versus objective memory change after temporal lobe epilepsy surgery
. 53:1511-1517.
1999
Evidence for the GluR6 gene associated with younger onset age of Huntington's disease
. 53:1330-1332.
1999
Clinical and laboratory features of primary progressive and secondary progressive MS
. 53:765-771.
1999
Cognitive consequences of coexisting temporal lobe developmental malformations and hippocampal sclerosis
. 53:709-715.
1999
Patient-oriented outcome assessment after temporal lobectomy for refractory epilepsy
. 53:687-694.
1999
Predictive value of
1
H MRSI for outcome in temporal lobectomy
. 53:694-698.
1999
Quantitative MRI in temporal lobe epilepsy: Evidence for fornix atrophy
. 53:496-501.
1999
Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults
. 52:321-327.
1999
Temporal lobe developmental malformations and hippocampal sclerosis epilepsy surgical outcome
. 52:479-484.
1999
Temporal lobe developmental malformations and hippocampal sclerosis: Epilepsy surgery outcome
. 53:694-698.
1999
Lesion laterality, neglect, and anosognosia.
. 51:920-921.
1998
1
H NMR spectroscopy studies of Huntington's disease. Correlations with CAG repeat numbers
. 50:1357-1365.
1998
A cross-reactive anti-myelin basic protein idiotope in cerebrospinal fluid cells in multiple sclerosis
. 50:411-417.
1998
Age-related changes in the level of urinary myelin basic protein-like material during childhood
. 51:1339-1341.
1998
Central poststroke pain and Wallenberg's lateral medullary infarction
. 50:1521.
1998
Central poststroke pain associated with lateral medullary infarction
. 50:837.
1998
Could pure alexia be due to a disconnection syndrome?
. 50:835.
1998
Topiramate increases brain GABA in healthy adults
. 51:627-629.
1998
Topiramate increases cerebral GABA in healthy humans
. 51:627-629.
1998
Clearing up misunderstandings about clinical trial methodology: a reply to Barnett et al.'s commentary on the ACAS Trial. ACAS Executive Committee, ACAS Data and Safety Monitoring Committee.
. 48:1743-1745.
1997
Differential diagnosis of Alzheimer's disease
. 48.
1997
Anterior translocation of language in patients with left cerebral arteriovenous malformation
. 49:802-808.
1997
Central poststroke pain and Wallenberg's lateral medullary infarction: Frequency, character, and determinants in 63 patients
. 49:120-125.
1997
Chromosome 17 and hereditary dementia: Linkage studies in three non- Alzheimer families and kindreds with late-onset FAD
. 48:949-954.
1997
Clearing up misunderstandings about clinical trial methodology: A reply to Barnett et al.'s commentary on the ACAS trial [2] (multiple letters)
. 48:1743-1748.
1997
Congenital porencephaly and hippocampal sclerosis: Clinical features and epileptic spectrum
. 49:1382-1388.
1997
Corticobasal degeneration: Neuropathologic and clinical heterogeneity
. 48:959-969.
1997
Epilepsy surgery outcome: Comprehensive assessment in children
. 48:1368-1374.
1997
Evidence for association of HLA-A2 allele with onset age of Alzheimer's disease
. 49:512-518.
1997
Hemianopic anosognosia
. 49:88-97.
1997
Krabbe continuum or clinical conundrum?
. 49:1203-1204.
1997
Oral phenylalanine loading in dopa-responsive dystonia: A possible diagnostic test
. 48:1290-1297.
1997
The role of dopamine agonists in early Parkinson's disease
. 49.
1997
Validation of the ACAS TIA/stroke algorithm
. 48:346-351.
1997
Apolipoprotein E ∈4 association with dementia in a population-based study: The Framingham Study
. 46:673-677.
1996
Increased risk of familial late-onset Alzheimer's disease in women
. 46:126-129.
1996
Mutation of the prion protein gene at codon 208 in familial Creutzfeldt- Jakob disease
. 47:1305-1312.
1996
Positive spontaneous visual phenomena limited to the hemianopic field in lesions of central visual pathways
. 47:408-417.
1996
Reply from the Author: Gender and AD
. 47:1358.
1996
Sorivudine: a promising drug for the treatment of varicella-zoster virus infection.
. 45:S73-S75.
1995
Circulating adhesion molecules and inflammatory mediators in demyelination: A review
. 45:S22-S32.
1995
Cytokine localization in multiple sclerosis lesions: Correlation with adhesion molecule expression and reactive nitrogen species
. 45:S16-S21.
1995
Familial progressive subcortical gliosis: Presence of prions and linkage to chromosome 17
. 45:1062-1067.
1995
Genetic anticipation in parkinson's disease
. 45:135-138.
1995
Inhibitory cytokines and cytokine inhibitors
. 45:S39-S43.
1995
No evidence for association of familial parkinson's disease with cag repeat expansion
. 45:1760-1763.
1995
Sorivudine: A promising drug for the treatment of varicella-zoster virus infection
. 45:S73-S75.
1995
VISUAL PHENOMENA LIMITED TO THE HEMIANOPIC FIELD IN LESIONS OF THE CENTRAL VISUAL PATHWAYS
. 44:A266-A266.
1994
A clinical genetic study of parkinson’s disease: Evidence for dominant transmission
. 44:499-506.
1994
Progressive supranuclear palsy: Neuropathologic and clinical heterogeneity
. 44:1015-1024.
1994
Capsular genu syndrome [7]
. 43:1862-1863.
1993
Chiari headaches
. 43:1272.
1993
Evidence for neuronal degeneration and dendritic plasticity in cortical pyramidal neurons of huntington's disease: A quantitative golgi study
. 43:2088-2096.
1993
Extrapersonal neglect [2]
. 43:1859-1860.
1993
Nonoptic aphasia: Aphasia with preserved confrontation naming in alzheimer's disease
. 43:1900-1907.
1993
Left hemiparalexia.
. 42:562-569.
1992
A syndrome of autosomal dominant alternating hemiplegia: Clinical presentation mimicking intractable epilepsy; chromosomal studies; and physiologic investigations
. 42:2251-2257.
1992
Confusion and memory loss from capsular genu infarction: A thalamocortical disconnection syndrome?
. 42:1966-1979.
1992
Kynurenine pathway abnormalities in Parkinson's disease
. 42:1702-1706.
1992
Left hemiparalexia
. 42:562-569.
1992
Subacute necrotizing encephalopathy: Oxidative phosphorylation defects and the ATPase 6 point mutation
. 42:2168-2174.
1992
MRI reveals multiple reversible cerebral lesions in an attack of acute intermittent porphyria.
. 41:1300-1302.
1991
Clozapine is beneficial for psychosis in parkinson's disease
. 41:1699-1700.
1991
Electrophysiologic analysis of early Parkinson’s disease
. 41:44-48.
1991
HLA-A2, or a closely linked gene, confers susceptibility to early-onset sporadic alzheimer’s disease in mene
. 41:1544-1548.
1991
Morphometric analysis of the prefrontal cortex in huntington’s disease
. 41:1117-1123.
1991
Sagittal sinus thrombosis and leptomeningeal medulloblastoma
. 41:455-456.
1991
United parkinson foundation neurotransplantation registry on adrenal medullary transplants: Presurgical, and 1– and 2–year follow–up
. 41:1719-1722.
1991
Progressive aphasia: A precursor of global dementia?
1990
Bodily neglect and orientational biases in unilateral neglect syndrome and normal subjects
. 40:640-643.
1990
Extrapyramidal involvement in Rett’s syndrome
. 40:293-295.
1990
Multiple sclerosis sibling pairs: Clustered onset and familial predisposition
. 40:1546-1552.
1990
Phenotypic heterogeneity of spinal muscular atrophy mapping to chromosome 5q11.2-13.3 (SMA 5q)
. 40:1831-1836.
1990
The intracarotid amobarbital procedure as a predictor of memory failure following unilateral temporal lobectomy
. 40:605-610.
1990
Transmission and age-at-onset patterns in familial alzheimer’s disease: Evidence for heterogeneity
. 40:395-403.
1990
Changes in survival after transient ischemic attacks: Observations comparing the 1970s and 1980s
. 39:982-985.
1989
Criteria for termination of phase II chemotherapy for patients with progressive or recurrent brain tumor
. 39:62-66.
1989
Ocular stroke and carotid artery dissection
. 39:1462-1464.
1989
Phenotypic variation in 2 huntington’s disease families with linkage to chromosome 4
. 39:1332-1336.
1989
Reply from the authors: Hemispatial neglect
. 39:458.
1989
Reply from the authors: Hemispatial neglect
. 39:1006.
1989
Seizures after primary intracerebral hemorrhage
. 39:1089-1093.
1989
Clinical and neuropathologic assessment of severity in huntington’s disease
. 38:341-347.
1988
Dopaminergic effects on simple and choice reaction time performance in Parkinson’s disease
. 38:249-254.
1988
Hemispatial neglect affected by non-neglected stimuli
. 38:1207-1211.
1988
Perseveration in behavioral neurology
1987
Aneurysmal compression of the anterior visual pathways
. 36:1035-1041.
1986
Krabbe disease: Specific MRI and CT findings
. 36:111-115.
1986
Dorsal midbrain syndrome in multiple sclerosis
. 31:196-198.
1981
Transient ischemic attacks: A prospective study of 225 patients
. 28:746-753.
1978
Metachromatic leukodystrophy: Comparison of early-and late-onset forms
. 27:933-941.
1977
Metrizamide encephalography: The use of a new, CSF soluble contrast agent
. 27:388.
1977
Stroke in a 15-year-old girl secondary to terminal carotid dissection
. 25:725-729.
1975
Subarachnoid hemorrhage caused by rupture of a small superficial artery
. 24:319-321.
1974
Neoplasms of the central nervous system: Epidemiologic considerations
. 22:40-48.
1972
Peripheral nerve glycolipids in metachromatic leukodystrophy
. 17:1033-1033.
1967
Steroid suppression of meningeal inflammation caused by pantopaque
. 9:48-52.
1959
Identity
International Standard Serial Number (issn)
0028-3878
1526-632X
Electronic International Standard Serial Number (eissn)
0028-3878
1526-632X